文献速递心胸血管麻醉

体外循环抗凝管理与肝素抵抗:心血管麻醉医师协会会员调查

Anticoagulation Management and Heparin Resistance During Cardiopulmonary Bypass: A Survey of Society of Cardiovascular Anesthesiologists Members.
PubMed 文献 · Anesth Analg · 2019-01-01

该调查向心血管麻醉医师协会会员发放问卷,了解体外循环抗凝实践及对肝素抵抗的态度。550名受访者中,74.9%采用经验性体重给药,70.7%以ACT 400或480秒为目标启动体外循环;17.1%的ACT目标低于2018年指南推荐或完全不监测肝素效应;遇到肝素抵抗时,54.2%首选抗凝血酶浓缩物。

要点

  • 多数受访者采用经验性体重肝素 dosing 并以ACT 400或480秒启动体外循环
  • 17.1%的ACT目标低于2018年STS/SCA/AmSECT指南推荐或未监测肝素效应
  • 肝素抵抗时54.2%首选抗凝血酶浓缩物作为一线治疗

核心结论

  • 心血管麻醉医师协会会员在体外循环抗凝实践中,多数采用经验性体重肝素给药和ACT 400或480秒目标,但仍有17.1%的实践低于2018年指南推荐或未监测肝素效应。

研究设计与样本

  • 向心血管麻醉医师协会会员发放问卷调查,共550名受访者,应答率18.5%。

主要发现

  • 74.9%(95%CI,71.3%-78.5%)的受访者使用经验性体重肝素给药。
  • 70.7%(95%CI,66.9%-74.5%)以ACT 400或480秒为目标启动体外循环。
  • 17.1%(95%CI,13.9%-20.2%)的受访者ACT目标低于2018年STS/SCA/AmSECT指南推荐或完全不监测肝素效应。
  • 遇到肝素抵抗时,54.2%(95%CI,50.0%-58.4%)的受访者首选抗凝血酶浓缩物治疗。

关键数值与推荐

  • 2018年STS/SCA/AmSECT指南推荐了体外循环抗凝的ACT目标,但原文未列出具体数值。

临床怎么用

  • 临床麻醉医生应参考2018年STS/SCA/AmSECT指南设定体外循环ACT目标,避免低于推荐值或不监测肝素效应。
  • 对肝素抵抗患者,可考虑将抗凝血酶浓缩物作为一线治疗选择。

局限性

  • 调查应答率仅为18.5%,可能存在无应答偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We surveyed Society of Cardiovascular Anesthesiologists members regarding anticoagulation practices for cardiopulmonary bypass and attitudes on heparin resistance. Of 550 respondents (18.5% response rate), 74.9% (95% CI, 71.3%-78.5%) used empiric weight-based dosing of heparin, and 70.7% (95% CI, 66.9%-74.5%) targeted an activated clotting time of either 400 or 480 seconds to initiate cardiopulmonary bypass. Of note, 17.1% (95% CI, 13.9%-20.2%) of respondents reported activated clotting time targets lower than those recommended by recent 2018 Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists/American Society of Extracorporeal Technology guidelines or failed to monitor heparin effects at all. When heparin resistance was encountered, 54.2% of respondents (95% CI, 50.0%-58.4%) administered antithrombin concentrates as a first-line therapy.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Sniecinski RM, Bennett-Guerrero E, Shore-Lesserson L, et al. Anticoagulation Management and Heparin Resistance During Cardiopulmonary Bypass: A Survey of Society of Cardiovascular Anesthesiologists Members. Anesth Analg. 2019. PMID: 30540616. doi:10.1213/ANE.0000000000003981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。